4D Molecular Therapeutics (FDMT) Consolidated Net Income: 2020-2025
Historic Consolidated Net Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Consolidated Net Income fell 29.68% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 45.83%. This contributed to the annual value of -$160.8 million for FY2024, which is 59.74% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Consolidated Net Income stood at -$56.9 million, which was down 4.14% from -$54.6 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Consolidated Net Income's 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$56.9 million in Q3 2025.
- In the last 3 years, 4D Molecular Therapeutics' Consolidated Net Income had a median value of -$34.9 million in 2024 and averaged -$38.3 million.
- Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 60.71% in 2023, then plummeted by 334.17% in 2024.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Consolidated Net Income stood at -$25.1 million in 2021, then fell by 9.20% to -$27.4 million in 2022, then declined by 17.86% to -$32.3 million in 2023, then crashed by 53.85% to -$49.6 million in 2024, then decreased by 29.68% to -$56.9 million in 2025.
- Its Consolidated Net Income stands at -$56.9 million for Q3 2025, versus -$54.6 million for Q2 2025 and -$48.0 million for Q1 2025.